The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

neximmune.com

Founded Year

2011

Stage

IPO | IPO

Total Raised

$36.94M

Date of IPO

2/12/2021

Market Cap

0.03B

Stock Price

1.28

About NexImmune

NexImmune (NASDAQ: NEXI) develops immunotherapy products based on its proprietary Artificial Immune Modulation nanotechnology platform, originally developed at Johns Hopkins University. NexImmune is based in Gaithersburg, Maryland.

NexImmune Headquarter Location

9119 Gaither Road

Gaithersburg, Maryland, 20877,

United States

(301) 825-9810

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NexImmune

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NexImmune is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

NexImmune Patents

NexImmune has filed 5 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/9/2019

5/18/2021

Clusters of differentiation, Immunology, Immune system, Transcription factors, Interleukins

Grant

Application Date

12/9/2019

Grant Date

5/18/2021

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Interleukins

Status

Grant

Latest NexImmune News

(5) Roundcube Webmail :: for BHI Website

Jul 18, 2022

First IND for NexImmune’s AIM nanoparticle platform in solid tumors IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-related cancers GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, has received IND clearance for the Company’s first cellular therapy product candidate addressing solid tumors.  NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), is being developed for patients with relapsed or refractory human papillomavirus (HPV)-related cancers. Kristi Jones, NexImmune’s CEO, commented, “The FDA clearance of our third IND marks another significant milestone for NexImmune and demonstrates our team’s continued focus and commitment to bringing novel therapies to patients with significant unmet need.  NEXI-003 is our third T cell therapy and first candidate to address solid tumors. NEXI-003 consists of T cell populations simultaneously directed against multiple HPV tumor-relevant antigen targets.  The T cells in our product candidate will consist of T cell subtypes critical to both potential anti-tumor activity and a phenotype intended to produce long-term immunologic memory required for durable responses.”

NexImmune Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NexImmune Rank

  • When was NexImmune founded?

    NexImmune was founded in 2011.

  • Where is NexImmune's headquarters?

    NexImmune's headquarters is located at 9119 Gaither Road, Gaithersburg.

  • What is NexImmune's latest funding round?

    NexImmune's latest funding round is IPO.

  • How much did NexImmune raise?

    NexImmune raised a total of $36.94M.

  • Who are the investors of NexImmune?

    Investors of NexImmune include Paycheck Protection Program, ArrowMark Partners, Multiple Myeloma Research Foundation, Piedmont Capital Partners, Barer & Son Capital and 9 more.

  • Who are NexImmune's competitors?

    Competitors of NexImmune include Tizona Therapeutics.

You May Also Like

ImCheck Therapeutics Logo
ImCheck Therapeutics

ImCheck Therapeutics designs and develops immunotherapy antibodies positioned at the crossroads of two high-potential immunological fields: g9d2 T cells and a novel super-family of immunomodulators, butyrophilins. Due to their mechanism of action, and notably their ability to simultaneously modulate innate and adaptive immunity, ImCheck's activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and when used in combination to overcome the resistance to this group of agents. In addition, preclinical experiments with ImCheck’s antagonist antibodies have demonstrated potential as treatments for a wide range of autoimmune diseases. ImCheck Therapeutics was founded in 2015 and is based in Marseille, France.

Tizona Therapeutics Logo
Tizona Therapeutics

Tizona Therapeutics is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system's function. In cancer, tumor cells evade recognition by controlling cells that suppress the proper function of the immune system. In autoimmune disease, the immune system attacks "self" tissues in the body due to insufficient regulation. Tizona's therapies are designed to regulate these suppressive cells, thereby either activating the body's ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases.

Tesaro Logo
Tesaro

Tesaro is an oncology-focused biopharmaceutical company devoted to providing therapies to people facing cancer. The company seeks to develop and commercialize new treatments.

G
GammaDelta Therapeutics

GammaDelta Therapeutics is an immunotherapy company developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.On October 27th, 2021, GammaDelta Therapeutics was acquired by Takeda Pharmaceutical. The terms of the transaction were not disclosed.

N
NewLink Genetics

NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing immunotherapeutic products to improve cancer treatment options for patients and physicians.

Incyte Logo
Incyte

Incyte seeks to build a product pipeline of small molecule drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.